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Autism spectrum disorder (ASD) is one of themost prevalent neurodevelopmental conditions worldwide. There
is growing awareness that ASD is highly comorbid with gastrointestinal distress and altered intestinal
microbiome, and that host-microbiome interactionsmay contribute to the disease symptoms. However, the pau-
city of knowledge on gut-brain axis signaling in autism constitutes an obstacle to the development of precision
microbiota-based therapeutics in ASD. To this end, we explored the interactions between intestinal microbiota,
gut physiology and social behavior in a BTBR T+ Itpr3tf/J mouse model of ASD. Here we show that a reduction
in the relative abundance of very particular bacterial taxa in the BTBR gut – namely, bile-metabolizing
Biﬁdobacterium and Blautia species, - is associated with deﬁcient bile acid and tryptophan metabolism in the in-
testine, marked gastrointestinal dysfunction, as well as impaired social interactions in BTBRmice. Together these
data support the concept of targetedmanipulation of the gutmicrobiota for reversing gastrointestinal and behav-
ioral symptomatology in ASD, and offer speciﬁc plausible targets in this endeavor.
©2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Autism spectrum disorder (ASD) is one of the most serious
neurodevelopmental conditions worldwide, affecting on average 1 in
150 children (Lyall et al., 2017). The hallmarks of ASD include impaired
social communication skills and repetitive behaviors, frequently co-oc-
curringwith intellectual disability (Association, 2013). There are limited
treatment options for ASD symptoms, and thus there is a great need to
develop strategies that would improve the quality of life in ASD sub-
jects. More recently, the gutmicrobiome has emerged as a novel impor-
tant player and therapeutic target in autism (Vuong and Hsiao, 2017).
Intestinal bacteria can orchestrate a range of gastrointestinal (GI) func-
tions (Sommer and Backhed, 2013), and therefore are poised to affect
gut-brain axis signaling in ASD. Animal studies have demonstrated
that the gut microbiota plays a crucial role in anxiety (Neufeld et al.,
2011), cognitive performance (Desbonnet et al., 2015), repetitive be-
haviors (Desbonnet et al., 2014) and social communications
(Bufﬁngton et al., 2016; Sherwin et al., 2017). There is a growing body
of evidence that ASD subjects display substantial alterations in microbi-
ota composition, along with marked symptoms of GI distress, including
changes to bowel habits, increased intestinal permeability, bloating and
abdominal pain (Angelis et al., 2013; D'Eufemia et al., 1996; Kang et al.,
2013; Luna et al., 2017; McElhanon et al., 2014; Tomova et al., 2015). In
a recent small open-label clinical study, transplantation of standardized
human gut microbiota to ASD-diagnosed children induced an improve-
ment of GI function, as well as a reduction of behavioral ASD scoring
(Kang et al., 2017). However, we do not yet know whether alterations
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in the gutmicrobiota in autism can in itself affect either behavioral or GI
symptoms of ASD.
Identiﬁcation of speciﬁc bacterial taxa and associated bacterial me-
tabolites that can trigger changes in GI physiology and modulate the
onset of autistic behaviors is thus an important quest in the search for
precision microbiota-based therapeutics in ASD (Gilbert et al., 2013).
Preclinical research is crucial in this endeavor (Hsiao et al., 2013;
Kumar and Sharma, 2016). The BTBR T+ Itpr3tf/J mouse strain is one of
the most widely used models of ASD. Similar to humans, these animals
display robust deﬁcits in social interactions and enhanced engagement
in repetitive behaviors (Meyza et al., 2013; Moy et al., 2007). Moreover,
the autistic-like behavior of BTBR mice is largely driven by multiple ge-
netic alterations (Meyza and Blanchard, 2017), but is also sensitive to
environmental inﬂuences, such as dietary intervention (Ruskin et al.,
2013). Changes to a few bacterial taxa have also been recently reported
in the BTBR intestine (Coretti et al., 2017; Klein et al., 2016; Newell et al.,
2016). Together, these ﬁndings strengthen the utility of the BTBR strain
in understanding dysfunctional microbiota-gut-brain signaling in ASD.
To this end, we characterized GI physiology in BTBR mice and found
substantial abnormalities in both intestinal barrier function and intesti-
nal transit. We identiﬁed changes in bile acid and tryptophan metabo-
lism as putative mechanisms underlying GI dysfunction in these
animals. We further associated the observed changes in GI physiology
with a reduction in the abundance of certain bacterial taxa in the BTBR
microbiota.
2. Materials and Methods
2.1. Animals
C57BL/6 J (Harlan, UK) and BTBR T+ Itpr3tf/J (The Jackson Laboratory,
US) adult male mice were group housed under a 12 h light-dark cycle;
standard rodent chow and water were available ad libitum. All experi-
ments were performed in accordance with European guidelines follow-
ing approval by University College Cork Animal Ethics Experimentation
Committee.
2.2. Study Design
Three independent cohorts participated in the study (Fig. S1). De-
tailed information on procedures with references is provided in Supple-
mental Methods.
2.3. Behavioral Assessment
Social behavior was analyzed in the three-chamber, social transmis-
sion of food preference and resident-intruder tests; compulsive behav-
ior in themarble burying and self-grooming tests; anxiety-like behavior
in the open ﬁeld and elevated plusmaze tests; depressive-like behavior
in the forced swim test; cognitive performance in the novel object rec-
ognition test.
2.4. Plasma Corticosterone in Response to an Acute Stressor
Corticosterone levels were measured in plasma prior to (baseline)
and after the onset of the forced swim test.
2.5. Fecal Water Content
Water content in feces was calculated as the difference in weight
after desiccation of fecal pellets.
2.6. Whole Intestinal Transit
A test mouse was administered with carmine dye by oral gavage; the
latency for the excretion of the ﬁrst red-colored fecal pellet was recorded.
2.7. Colonic Transit
An artiﬁcial pellet was inserted into the proximal end of the isolated
colon, and the spontaneous propagation of the pellet in anterograde di-
rection was video recorded. The latency to initiate the propagation and
the velocity of propagation were scored.
2.8. Intestinal Permeability
Intestinal tissue samples were mounted into the Ussing chambers.
Short-circuit current (Isc) was recorded in a zero voltage clamp mode;
transepithelial electrical resistance (TEER) was measured by
discharging a 2mVpulse. 4 kDa FITC-dextranwas added to themucosal
chamber at aﬁnal concentration of 2.5mg/mL; 200 μL sampleswere col-
lected from the serosal chamber every 30 min for the following 3 h.
2.9. Myenteric Plexus Morphology
Myenteric plexus (MP) of distal colon was subjected to
immunoﬂourescent staining against choline acetyltransferase (ChAT),
HuC/HuD and nNOS. To analyze the morphology of MP, the following
parameters were calculated in anti-ChAT stained tissues: the area occu-
pied by MP; the mean thickness and the contact ratio of MP; the mean
Feret diameter of interganglionic space. The numbers of HuC/HuD-
and nNOS-positive myenteric neurons were quantiﬁed per visual ﬁeld.
2.10. Tryptophan, Kynurenine and Serotonin Levels
Serotonin was measured in intestinal tissue samples by HPLC
coupled to electrochemical detection. Kynurenine and tryptophan con-
centrations were determined in plasma by HPLC coupled to ultraviolet
(230 nm) and ﬂuorescent (254 nm excitation and 404 nm emission
wavelengths) detection, accordingly.
2.11. Gene Expression Analysis
Total RNAwas extracted from the intestinal tissue and the front lobe
of the liverwith theQiagen RNeasy Plus UniversalMini kit, and from the
right hippocampus with the Ambion mirVana™ miRNA Isolation Kit.
Genes of interest were ampliﬁed with real-time RT-PCR using TaqMan
probes (Table S1). Data were analyzed with the comparative cycle
threshold method (2−ΔΔCt) and presented as a fold change vs. C57BL/
6 group.
2.12. Bile Acid Levels in Plasma and Fecal Material
Fecal and plasma bile acids and salts were extracted following addi-
tion of deuterated internal standards (IS). Extracted acids were resus-
pended in 50% methanol, injected in triplicate and assessed in
negative electrospray mode through a C18 Acquity column using a
LCT Premier mass spectrometer (Waters Corp). Assessment of extrac-
tion efﬁciency was performed using IS, and samples were quantiﬁed
by standard curve construction for individual bile moieties using
targetlynx software (Waters).
2.13. Microbiota Composition and Short Chain Fatty Acids Analysis in the
Cecal Content
DNAwas extracted using the Qiagen QIAmp Fast DNA Stool Mini Kit
coupled with an initial bead-beating step. The V3-V4 hypervariable re-
gion of the 16S rRNA gene was ampliﬁed and prepared for sequencing
as outlined in the Illumina 16S Metagenomic Sequencing Library Proto-
col. Samples were sequenced at Clinical-Microbiomics (Copenhagen,
Denmark) on the Illumina MiSeq platform using a 2 × 300 bp kit.
Reads were assembled, processed and analyzed following the pipeline,
described in Supplemental Methods. Short chain fatty acids (SCFAs)
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were measured by gas chromatography, using a Varian 3500 GC ﬂame-
ionization system ﬁtted with a ZB-FFAP column.
2.14. Statistical Analysis
Normally distributed data are presented as mean ± SEM; unpaired
two-tailed t-test and mixed-design ANOVA were applied to analyze
the differences between groups. Non-parametric datasets, as well as
discrete data, are presented as median (IQR). Mann-Whitney test was
used for between-group comparisons. Spearman's rank correlation co-
efﬁcient was employed for the correlation analysis in the pooled
datasets. A p value b 0.05 was deemed signiﬁcant in all cases.
3. Results
3.1. BTBR Mice Display Marked Changes in the Intestinal Microbiota
The 16S sequencing revealed a substantial reduction in the bacterial
species diversity in the BTBR cecum (Fig. 1a). Principal coordinate anal-
ysis showed a clear separation of BTBR and C57BL/6 microbiotas (Fig.
1b). We detected 9 phyla, 23 families and 41 bacterial genera in
C57BL/6 and BTBR mice (Table S2). At the phylum level, BTBR mice
displayed a distinct shift towards an increase in Bacteroidetes and a de-
crease in Firmicutes; these are two major bacterial phyla altogether
comprising N90% of murine intestinal microbiota (Fig. 1c). The bloom
in Bacteroidetes was mainly driven by an increase in S24–7 uncultured
bacterium, a dominant genus of S24–7 family. Interestingly, this seems
to have happened at the expense of minor Bacteroidetes genera such
as Odoribacter, Parabacteroides, RC9 gut group and Rikenella, which all
showed a reduction in relative abundance. A decrease in Firmicutes
was largely driven by Lachnospiraceae family, in particular Blautia bacte-
ria, but also Lachnospiraceae_Incertae Sedis and Coprococcus. BTBR mice
also displayed an increase in Akkermansia, Bacteroides and Bilophila gen-
era, as well as a reduction in Biﬁdobacterium and Desulfovibrio (Table
S2). With such a prominent shift in the microbiota composition, it was
perhaps not surprising that BTBRmice also displayed signiﬁcant chang-
es in the SCFAs levels in the gut lumen (Fig. 1d). Overall, BTBR mice
seem to have a very robust phenotype of the gut microbiota. For exam-
ple, a similar increase in Akkermansia and a reduction in Biﬁdobacterium
numbers in the BTBR cecum were shown in previous reports (Klein et
al., 2016; Newell et al., 2016). In the fecal material of BTBRmice, Coretti
et al. found a different pattern of changes in themicrobiota composition
(Coretti et al., 2017); however, care should be taken when comparing
cecal and fecal bacterial communities.
Fig. 1. Altered microbiota composition and short chain fatty acid levels in BTBR mice (a–b) BTBR cecal microbiota showed lower diversity of bacterial species, and was clearly separated
from the microbiota of C57BL/6 mice. (c) Heatmap of log2 fold change ratio showing increases (red) or decreases (blue) in most abundant bacteria in BTBR compared to C57BL/6 mice.
Signiﬁcant changes are bolded (for details, see Table S2). (d) Short chain fatty acid cecal levels were differentially changed in BTBR mice. *p b 0.05 for BTBR vs. C57BL/6 group.
Statistical analysis: data are presented as median with IQR and min/max values as error bars on (a), and as mean + SEM on (d). N= 9 for C57BL/6 and N= 10 for BTBR group. U(17)
= 0.000, p b 0.0005 for Chao1 index; U(17) = 15.5, p = 0.013 for Simpson index; U(17) = 0.000, p b 0.0005 for Shannon index; U(17) = 0.000, p b 0.0005 for No of species, Mann-
Whitney test. t(17) = 2.424, p = 0.027 for acetate; t(17) = −0.265, p = 0.794 for propionate; t(17) = −2.887, p = 0.010 for n-butyrate; t(17) = 4.023, p = 0.001 for i-butyrate,
unpaired t-test.
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3.2. BTBR Mice Show Delayed Intestinal Transit
Among GI comorbidities associated with ASD, changes in bowel
habits, in particular constipation, are the most prevalent (McElhanon
et al., 2014). Hence, we examined intestinal motility, and found that
whole intestinal transit was signiﬁcantly delayed in BTBR mice (Fig.
2a). Further, BTBR mice displayed an elongated colon and decreased
fecal water contents (Fig. 2b–c), both observations suggesting that the
propagation of fecal matter along the colon was substantially slowed.
The follow-up ex vivo analysis of colonic motility provided clear evi-
dence of impaired transit in the BTBR large intestine. Indeed, it took al-
most twice as long to initiate spontaneous propagation of the pellet
along the colon, and there was a trend towards a reduction in the veloc-
ity of oral-to-anal propulsion in BTBR mice (Fig. 2d). Measuring small
intestinal transit in BTBR mice would be of interest for the future
studies, particularly bearing in mind that impaired small intestinal mo-
tility was previously reported in a rat model of ASD (Kim et al., 2013).
3.3. Impaired Serotonin Production in the BTBR Intestine
The release of mucosal serotonin (5-HT) triggers intestinal peristal-
sis (Heredia et al., 2013). To address the potential contribution of 5-HT
metabolism to the delayed transit in the BTBR intestine, we assessed
5-HT availability in colonic and ileal tissue samples. We observed a
50% reduction in 5-HT tissue levels in both small and large intestine of
BTBR mice, which was coupled with a down-regulation of Tph1 and an
up-regulation of Sert gene expression (Fig. 2e–f). Tph activity deter-
mines the amount of 5-HT which is produced from dietary tryptophan
and released from enterochromafﬁn cells, while Sert controls the rate
of 5-HT re-uptake and consequent breakdown in enterocytes (Mawe
Fig. 2. Delayed intestinal transit and impaired serotonin metabolism in BTBR mice: implication of microbiota (a–c) BTBR mice showed delayed whole intestinal transit, as well as an
elongated colon and decreased fecal water contents. (d) Colonic transit was impaired in BTBR mice. (e–f) Serotonin (5-HT) tissue levels were reduced in both small and large intestine
of BTBR mice. This was coupled with alterations in the expression of genes involved in tryptophan metabolism. (g) Intestinal transit rate and 5-HT levels were strongly associated with
the relative abundance of Blautia bacteria (see also Table S3). *p b 0.05 for BTBR vs. C57BL/6 group. Statistical analysis: data are presented as mean + SEM; n= 8 for C57BL/6 and n=
6 for BTBR group for (d), n= 9–10 in either group for the rest. t(18) =−4.524, p b 0.0005 for the intestinal transit time; t(18) =−14.053, p b 0.0005 for the colon length; t(12) =−
4.107, p= 0.001 for the latency to initiate propagation; t(11) = 1.599, p= 0.138 for the propulsive activity; t(17) = 3.597, p= 0.002 for 5-HT levels and t(15) =−1.814, p= 0.09 for
5-HT/5-HIAA ratio in the colon; t(17) = 5.069, p b 0.0005 for Tph1, t(18) = 1.928, p= 0.070 for P11, t(16) = 4.578, p= 0.003 for Ido1, t(18) = 3.835, p= 0.006 for Tdo2 and t(18) =−
4.851, p b 0.0005 for Sert gene expression in the colon; t(17) = 4.164, p= 0.001 for 5-HT levels and t(8) =−0.930, p= 0.380 for 5-HT/5-HIAA ratio in the ileum; t(17) = 2.311, p=
0.034 for Tph1, t(17) = 2.533, p= 0.021 for P11, t(16) = 9.546, p b 0.0005 for Ido1, t(18) =−14.655, p b 0.0005 for Sert and t(18) =−2.739, p= 0.013 for Tdo2 gene expression in the
ileum, unpaired t-test. Spearman's rho was employed for the correlation analysis in the pooled datasets.
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and Hoffman, 2013). In line with the gene expression data, the ratio be-
tween 5-HIAA (themajormetabolite of 5-HT) and 5-HT tended to be in-
creased in the BTBR intestine (Fig. 2e–f). Together, these ﬁndings
suggest reduced bioavailability of 5-HT in the BTBR gut due to a de-
crease in 5-HT synthesis and an increase in 5-HT breakdown. Alterna-
tively to 5-HT, dietary tryptophan in the intestine can be metabolized
along the kynurenine route. Ido1 and Tdo2 are two rate-limiting en-
zymes in this metabolic pathway. We found that the expression levels
of both Ido1 and Tdo2 genes were markedly down-regulated in the
BTBR colon. Interestingly, opposite changes in Ido1 and Tod2 genes
were observed in the small intestine of BTBR mice (Fig. 2e–f).
3.4. Intestinal Transit and Serotonin Levels Correlate with the Abundance of
Certain Bacterial Taxa
Gut microbes, in particular spore-forming clostridia, have been
shown to regulate 5-HT metabolism in the GI tract (Yano et al., 2015).
To this end, we investigatedwhether observed changes in the intestinal
transit and 5-HT levels in the gutwere associatedwith alterations in the
abundance of any particular bacterial taxa.We found that both 5-HT tis-
sue levels and intestinal transit rate were strongly correlated with the
relative abundance of Firmicutes bacteria; this correlation was mainly
driven by the Blautia genus of the Clostridiales order (Fig. 2g). There
were also strong correlations between the abundance of Blautia and
Tph1, Sert and Ido1 gene expression levels (Table S3). Similar, but weak-
er associations were observed with the Lachnospiraceae Incertae Sedis
genus of the same order. These ﬁndings conﬁrm the importance of clos-
tridia bacteria in the maintenance of normal peristalsis and 5-HT syn-
thesis in the gut.
3.5. BTBR Mice Display Deﬁcits in the Development of the Enteric Nervous
System
Healthy motility of the GI tract relies heavily on the enteric nervous
system (ENS). We thus aimed to investigate whether delayed colonic
transit in BTBRmice could have also been attributed to abnormal devel-
opment of motor circuits in the ENS. For this, we stained the myenteric
plexus (MP) in distal colon against choline acetyltransferase (ChAT),
which is expressed in a vast majority of myenteric neurons including
excitatory motor neurons, and against neuronal NO synthase (nNOS),
which is expressed in inhibitory motor neurons of MP (Furness,
2000). ChAT staining showed the ﬁne structure of MP with ganglia
and interganglionic ﬁbers (Fig. 3a). Themorphometric analysis revealed
a substantial reduction in the spatial density of MP in BTBR mice: the
area occupied by MP was decreased, while the interganglionic space
was increased (Fig. 3b). Furthermore, we found a 50% reduction in the
numbers of inhibitory motor neurons (nNOS) and total myenteric neu-
rons (pan-neuronal HuC/HuD marker) (Fig. 3c–d). These data suggest
an abnormal development of both excitatory and inhibitory motor neu-
rons in BTBR mice. These are interesting data in the context of recent
ﬁndings indicating that the gut microbiota is essential for the develop-
ment of the ENS (Collins et al., 2014; Obata and Pachnis, 2016).
3.6. BTBRMice Have Differential Changes in Epithelial Permeability in Small
and Large Intestine
Along with altered bowel habits, ASD has been associated with im-
paired intestinal barrier function (D'Eufemia et al., 1996; de Magistris
et al., 2010; Fiorentino et al., 2016). To characterize epithelial perme-
ability in the BTBR intestine, we measured the efﬁcacy of macromolec-
ular diffusion across the epithelium ex vivo (4 kDa FITC ﬂux). In the
distal ileum, we observed a dramatic increase in epithelial permeability
in BTBR mice (Fig. 4a). FITC ﬂux was increased approximately two-fold
at the 60 min time point and remained consistently elevated over the
next two hours of the assay (p = 0.019 for the effect of genotype,
F(1;14) = 7.090). Macromolecular permeability of intestinal epithelium
is largely dependent on the proper function of tight junctions (TJs)
(Zihni et al., 2016). Despite an increase in FITC ﬂux, we failed to ﬁnd
substantial alterations in the gene expression levels of either TJ proteins
(Cldn1, Ocln and Tjp1) or proteins regulating the assembly and energy
supply to TJs (Ckb, Ckm, Mylk) (Glover et al., 2013; Shen et al., 2006)
(Fig. 4b).
Colonic tissue showed a very distinct proﬁle of macromolecular per-
meability in BTBR mice (Fig. 4c). During the ﬁrst 90 min of the assay,
FITC ﬂux was slightly decreased (p=0.002 for the time × genotype in-
teraction, F(6;102) = 9.198; p = 0.003 for 60 min and p = 0.057 for
90 min). However, during the following 90 min, FITC ﬂux in BTBR sam-
ples substantially accelerated, overtaking the control group and
reaching signiﬁcantly higher levels by the end of the assay (p= 0.029
for 180 min). Gene expression analysis shed some light on the biphasic
response of FITC permeability (Fig. 4d). On one hand, a marked increase
in Cldn1 gene expression can explain a functionally “tighter” epithelium
in the BTBR colon at baseline. On the other hand, a 50% down-regulation
of creatine kinase Ckb and Ckm genes suggests a reduced efﬁcacy of
phosphocreatine metabolic shuttle turnover, which is critically impor-
tant for the maintenance of energy supply to TJs (Glover et al., 2013).
This would favor a rapid increase in macromolecular permeability in
BTBR samples in ex vivo conditions, when tissue specimens are exposed
to limited oxygen and substrate supply. Furthermore, these ﬁndings
suggest that the BTBR colon might be less resilient to any metabolic
stress in vivo, such as intestinal inﬂammation or hypoxia.
The epithelialmucus layer also helps tomaintain the physical barrier
between the gut and the lumen (Johansson et al., 2011). Interestingly,
the expression of Muc2, a gene encoding mucin 2, which is the major
constituent of mucus layer, was down-regulated in the large intestine
of BTBR mice, but not in distal small intestine (Fig. 4e). Despite marked
alterations in FITC permeability, only marginal changes in ion conduc-
tance (TEER) were observed in either ileum or colon samples of BTBR
mice (Fig. 4f, left panel). Although at ﬁrst glance counterintuitive,
these ﬁndings are supported by the current model of junctional gate
(Zihni et al., 2016), whereby ions andmolecules use different pathways
to diffuse through the tight junction. TEER and macromolecular perme-
ability of the intestinal epithelium can thus be differentially regulated
and even functionally decoupled (Balda et al., 1996).
3.7. Reduced Activity of Electrolyte Transport in the BTBR Intestine
Weanalyzed Isc values in BTBR and C57BL/6 intestine as ameasure of
electrolyte transport across the epithelium. In both small and large in-
testine, Isc was substantially decreased in BTBR mice (Fig. 4f, right
panel). This suggests either a reduction in Na+ absorption from the
gut lumen and/or a decrease in Cl− secretion into the lumen. Interest-
ingly, we observed a down-regulation of Slc5a1 gene in the BTBR
ileum (Fig. S2a). Slc5a1 encodes apical Na+/glucose co-transporter,
which is known to enhance intestinal Isc in the presence of luminal glu-
cose (Berglund et al., 2001; Turner et al., 1997). Activation of Cl− secre-
tion in the colon is associated with water retention in the lumen and,
when reaching pathological levels, diarrhea (Thiagarajah and
Verkman, 2012). In this regard, a reduction in Cl− secretion in the
BTBR colon would be consistent with decreased fecal water contents
and delayed colonic transit (Fig. 2b–d).
3.8. Intestinal Permeability Correlates With the Abundance of Certain Bac-
terial Taxa
Gut bacteria and their metabolites can modulate intestinal barrier
function (Kelly et al., 2015); therefore, we examined the associations
between microbiota composition and intestinal macromolecular per-
meability (Table S3). Interestingly, herewe observed a different correla-
tion proﬁle in comparison with the one found for intestinal transit and
5-HTmetabolism. From the Firmicutes phylum, correlationswith Blautia
genus were largely lost. Instead, a strong negative association between
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the abundance of Ruminococcaceae Incertae Sedis bacteria and FITC per-
meability was observed. In Bacteroidetes, a strong positive correlation
between FITC ﬂux and S24–7 uncultured bacterium abundancewas pres-
ent. Many of these differences can be driven by a uniquemetabolic pro-
ﬁle of each bacterial genus, including the production of different
biologically active compounds, such as SCFAs or indoles (Kennedy et
al., 2017; Sandhu et al., 2017).
3.9. BTBR Mice Display Reduced Plasma Bile Acid Levels and Deﬁcient Bile
Acid Signaling in the Ileum
Epithelial permeability data (Fig. 4) clearly demonstrated functional
differences between the colon and the ileum in BTBR mice. One of the
unique features of the terminal small intestine is the active uptake of
the bile from the intestinal lumen (de Aguiar Vallim et al., 2013). Pri-
marily, bile acids (BAs) assist in the digestion of dietary lipids and regu-
late lipid metabolism. In the small intestine, they are also very
important for the maintenance of epithelial barrier function (Gadaleta
et al., 2011; Inagaki et al., 2006). Hence, we measured BAs in plasma
and fecalmatter of BTBR and C57BL/6mice (Fig. 5 and Table S4). In plas-
ma, the levels of tauro-conjugated and unconjugated BAs were overall
decreased in BTBR mice (Fig. 5a). About 95% of the bile released into
the gut is actively re-absorbed in distal ileum to ensure the complete
enterohepatic circulation. Thus, a decrease in plasma BAs in BTBR mice
could be attributed to a deﬁcit in either BA synthesis or BA re-uptake.
We did not ﬁnd any changes in the gene expression of intestinal BA
transporters (Asbt, Fabp6, Ostα) or liver BA transporters (Ntcp, Bsep)
across the groups (Fig. 5b–c). These ﬁndings rule out the BAmalabsorp-
tion in BTBRmice. Instead, there was a trend towards a reduction in the
expression of Cyp7a1 gene,which encodes a rate-limiting enzyme in the
classical pathway of BA synthesis in the liver (Fig. 5c). Interestingly, the
expression of Cyp7b1 gene,which encodes a rate-limiting enzyme in the
alternative pathway of BA synthesis, was up-regulated in BTBR mice.
When absorbed in distal ileum, BAs activate the farnesoid X receptor
Fig. 3. BTBRmice display deﬁcits in the development of the enteric nervous system (a) Anti-ChAT staining (green) inwholemount preparations of distal colon revealed the ﬁne structure
ofmyenteric plexus (MP), with ganglia and interconnecting ﬁbers. Cellular nuclei were stainedwith DAPI (blue). (b) The spatial density of MPwas decreased in BTBRmice. (c)Myenteric
ganglia were co-stained against pan-neuronal marker HuC/HuD (green) and nNOS (red). (d) BTBR mice showed a reduction in total and nNOS-positive neuronal numbers. Scale bar
represents 100 μm *p b 0.05 for BTBR vs. C57BL/6 group. Statistical analysis: data are presented as median with IQR and min/max values as error bars; n= 5 in either group. U(9) =
0.000, p = 0.004 for MP area; U(9) = 30.000, p = 0.004 for interganglionic space; U(9) = 6.000, p = 0.126 for MP contact ratio; U(9) = 5.000, p = 0.082 for MP thickness; U(8) =
0.000, p= 0.008 for HuC/HuD neurons; U(8) = 0.000, p= 0.008 for nNOS neurons, Mann-Whitney test.
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(FXR) in enterocytes. The expression levels of Fxr gene, as well as its
partners Rxrα and Hnf4α, were unchanged in the BTBR ileum (Fig. 5b).
However, the downstream targets of this receptor, in particular Fgf15
and Nos2, were substantially down-regulated. Intestinal Fgf15 is a po-
tent inhibitor of Cyp7a1 expression and BA synthesis (Kong et al.,
2012). Hence, it is surprising that the suppression of the intestinal Fxr/
Fgf15 signaling pathway failed to up-regulate Cyp7a1 gene expression
in the liver of BTBR mice. On the other hand, Cyp7a1 expression can
be activated by the nuclear receptors Pgc-1α and Ppar-γ (Duan et al.,
2012; Shin et al., 2003). Similar to Cyp7a1, the expression levels of
both Pgc-1α and Pparγ genes were decreased in the BTBR liver (Fig.
5c), suggesting that multiple nuclear receptors are implicated in the de-
creased BA synthesis observed in BTBR mice.
3.10. BTBR Mice Display a Deﬁcit in the Microbial Conversion of Bile
Bile that is not re-absorbed in terminal small intestine undergoes
further transformation by the intestinal microbiota (Joyce and Gahan,
2016). First, gut bacteria de-conjugate BAs from taurine and glycine.
Second, unconjugated primary BAs (cholic acid (CA), chenodeoxycholic
acid (CDCA) andmuricholic acid (MCA) inmice) are processed into sec-
ondary BAs, such as deoxycholic acid (DCA), lithocholic acid (LCA) and
Fig. 4. Differential changes to epithelial permeability and tight junction-associated gene expression in small and large intestine of BTBR mice (a) In distal ileum, BTBR mice showed a
marked increase in FITC transepithelial permeability, with no substantial changes to either tight junction-associated genes (b) or mucin2 gene expression (e). (c) In the colon of BTBR
mice, FITC permeability was increased in the end, but decreased in the beginning of the incubation period. The biphasic response of FITC ﬂux was coupled with an up-regulation of
tight junction protein genes, but a down-regulation of creatine kinase and mucin2 genes (d–e). (f) TEER was not changed, while Isc was substantially decreased in the BTBR intestine.
*p b 0.05 for BTBR vs. C57BL/6 group. Statistical analysis: data are presented as mean + SEM, n= 10 in either group. FITC permeability in distal ileum: F(6;84) = 63.339, p b 0.0005 for
the effect of Time, F(1;14) = 7.090, p = 0.019 for the effect of Genotype, F(6;84) = 7.177, p = 0.015 for the Time × Genotype interaction. FITC permeability in the colon: F(6;102) =
383.858, p b 0.0005 for the effect of Time, F(1;17) = 0.061, p = 0.808 for the effect of Genotype, F(6;102) = 9.198, p = 0.002 for the Time × Genotype interaction. Datasets were
analyzed with mixed-design ANOVA with Genotype as an independent factor and Time as a repeated measure. Mean values in each time point were further compared between
groups with unpaired t-test. t(14) = 1.582, p= 0.136 for TEER; t(14) = 6.862, p b 0.0005 for Isc; t(18) = 0.624, p= 0.541 for Cldn1, t(18) =−1.429, p= 0.170 for Ocln, t(18) =−2.768,
p = 0.013 for Tjp1, t(15) = −3.292, p = 0.005 for Ckb, t(16) = −3.731, p = 0.002 for Ckm, t(15) = 0.217, p = 0.831 for Mylk, t(17) = 1.278, p = 0.218 for Muc2 gene expression in
distal ileum, unpaired t-test. t(18) = 1.101, p= 0.285 for TEER; t(18) = 4.407, p= 0.001 for Isc; t(18) =−6.319, p b 0.0005 for Cldn1, t(18) =−2.273, p= 0.035 for Ocln, t(18) = 0.104,
p = 0.918 for Tjp1, t(17) = 4.791, p b 0.0005 for Ckb, t(17) = 3.255, p = 0.005 for Ckm, t(17) = 5.751, p b 0.0005 for Mylk, t(17) = 6.261, p b 0.0005 for Muc2 gene expression in the
colon, unpaired t-test.
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ursodeoxycholic acid (UDCA). In the fecal matter of BTBR mice, we ob-
served a remarkable increase in all conjugated BAs, for both primary
and secondary conjugates (Fig. 5d, right panel). Further,we sawa signif-
icant reduction in secondary bile acid LCA, with a similar trend in DCA
and UDCA (Fig. 5d, left panel). Moreover, the ratio between secondary
and primary unconjugated BAs was signiﬁcantly decreased in BTBR
mice (Fig. S3). These data indicate that the BTBR microbiota has a re-
duced capacity to metabolize host bile.
3.11. Changes in the Gut Microbiota are Associated with a Robust Autistic-
like Behavioral Phenotype
We characterized the ASD-relevant behavioral phenotype in BTBR
mice (Fig. 6). In agreement with previous reports (Meyza et al., 2013),
BTBR mice demonstrated impaired social interactions (a–c) and en-
hanced engagement in repetitive behaviors (e–f), as well as increased
anxiety levels (h–k). Here we found decreased levels of social
Fig. 5. Altered bile acid signatures and deﬁcient bacterial metabolism of bilemoieties in BTBRmice (a) In plasma, a reduction in unconjugated and tauro-conjugated BA levels was seen in
BTBRmice. (b–c) The gene expression levels of BA transporters were not altered in the distal ileum or liver of BTBRmice. In contrast, Cyp7a1 and Pparg genes in the liver, as well as Fgf15
and Nos2 genes in the ileumwere down-regulated in BTBRmice. (d) In the fecal matter of BTBRmice, a dramatic increase in all tauro-conjugated BAs and a trend towards a reduction in
unconjugated secondary BAs were observed. *p b 0.05 for BTBR vs. C57BL/6 group. Statistical analysis: data are presented asmedian with IQR andmin/max values as error bars on (a) and
(d), and as mean+ SEM on (b) and (c). U(11)= 11.000, p=0.181 for total BAs,U(11)= 7.000, p=0.051 for CA, U(11) = 2.000, p=0.005 for CDCA, U(11)= 19.000, p=0.836 for β-MCA,
U(10)=1.500, p=0.005 for DCA,U(11)= 25.000, p=0.628 for LCA,U(11)=0.000, p=0.001 for UDCA,U(10)= 10.000, p=0.268 for total TBAs,U(10)=13.000, p=0.530 for TCA,U(10)=
5.000, p= 0.048 for TCDCA, U(10) = 8.000, p= 0.149 for Tβ-MCA, U(10) = 10.000, p= 0.268 for TDCA, U(10) = 27.000, p= 0.149 for TLCA, U(10) = 2.000, p= 0.010 for TUDCA levels in
plasma, n=7 inC57BL/6 and n=6 inBTBR group,Mann-Whitney test.U(11)= 16.000, p=0.534 for total BAs,U(11)= 25.000, p=0.628 for CA,U(11)= 17.000, p=0.628 for CDCA,U(11)
= 34.000, p=0.073 for β-MCA,U(11)= 10.000, p=0.138 for DCA,U(11)= 6.000, p=0.035 for LCA,U(11)= 10.000, p=0.138 for UDCA,U(11)= 39.000, p=0.008 for total TBAs,U(11)=
35.000, p=0.051 for TCA, U(11) = 37.000, p=0.022 for TCDCA, U(11) = 38.000, p=0.014 for Tβ-MCA, U(11) = 40.000, p=0.005 for TDCA, U(11) = 39.000, p=0.008 for TLCA, U(11) =
42.000, p=0.001 for TUDCA levels in the fecalmatter, n=7 inC57BL/6 andn=6 inBTBRgroup,Mann-Whitney test. t(18)=−0.081, p=0.936 for Fxr, t(18)=−0.488, p=0.632 forRxra,
t(18) =−0.726, p=0.477 for Hnf4a, t(17) = 2.776, p=0.013 for Fgf15, t(18) = 2.807, p=0.012 for Nos2, t(18) =−0.102, p=0.920 for Asbt, t(18) =−0.373, p=0.714 for Fabp6, t(18) =
−0.118, p= 0.907 for Osta gene expression in distal ileum, n = 10 in either group, unpaired t-test. t(11) = 1.887, p= 0.086 for Cyp7a1, t(12) =−3.157, p= 0.008 for Cyp7b1, t(12) =
−0.274, p = 0.788 for Fxr, t(12) =−0.905, p = 0.383 for Rxra, t(12) =−0.525, p = 0.609 for Hnf4a, t(11) = 3.189, p = 0.009 for Pparg, t(12) = 2.190, p = 0.061 for Pgc-1a, t(12) =
0.167, p= 0.870 for Ntcp, t(12) =−0.274, p= 0.788 for Bsep gene expression in the liver, n= 8 in C57BL/6 and n = 6 in BTBR group, unpaired t-test.
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behavior-related hormone oxytocin in BTBR plasma (d). Further, BTBR
mice displayed higher baseline levels of the stress hormone corticoste-
rone, as well as elevated corticosterone values at the peak of the acute
stress response and during the subsequent recovery phase (Fig. 6l, p b
0.05 for the effect of genotype, F(1;16) = 8.193). Despite this hyper-cor-
ticosterone phenotype, BTBR mice had smaller adrenal glands, and in-
creased expression of the glucocorticoid receptor gene in the
hippocampus (Fig. 6m–n). Interestingly, the expression of Cyp11a1, a
gene encoding the ﬁrst rate-limiting enzyme in the production of corti-
costerone, was substantially up-regulated in the distal ileum of BTBR
mice (Fig. S2b). Taken on its own, this transcriptional shift does not
necessarily implicate an increase in intestinal hormonal levels. Howev-
er, if local production of corticosterone was elevated in the BTBR ileum,
this could explain increased levels of circulating hormone (Fig. 6l)
(Mukherji et al., 2013). This could also affect the GI physiology in
BTBR mice including an up-regulation of Tdo2 gene in distal ileum
(Fig. 2f, see also Discussion).
Correlation analysis between the relative abundance of bacterial
taxa and behavioral scores showed an impressively strong association
between the gut microbiota and the behavioral phenotype (Fig. 7).
Rikenella, Parabacteroides, Odoribacter, Desulfovibrio, Blautia and
Biﬁdobacterium species (all reduced in abundance in BTBR mice) were
Fig. 6.Autistic-like behavioral phenotype inBTBRmice (a–d)BTBRmice displayed impaired social interactions, aswell as decreasedplasma levels of oxytocin. (e–f) BTBRmicewere largely
engaged in compulsive behaviors. They showed impaired working memory performance (g), enhanced locomotor activity and anxiety-like behavior (h, i and k). (j) No evidence of
depressive-like behavior was observed. (l) BTBR mice displayed elevated plasma corticosterone levels at baseline and when being exposed to an acute stressor (forced swim test). (m–
n) BTBR mice had smaller adrenal glands and increased expression of glucocorticoid receptor gene in the hippocampus. *p b 0.05 for BTBR vs. C57BL/6 group. Statistical analysis: data
are presented as median with IQR and min/max values as error bars on (e) and (k), and as mean + SEM on the rest, n = 10 in either group. t(18) = 8.153, p b 0.0005 for Mouse vs
Object and t(17) = 3.707, p= 0.002 for Novel vs Familiar Mouse preference; t(18) = 5.678, p b 0.0005 for the RI interaction; t(13) = 3.485, p= 0.004 and t(13) = 2.029, p= 0.063 for
the cued food preference at 0 h and 24 h time points, respectively; t(17) = 3.623, p= 0.002 for oxytocin levels; t(18) =−6.303, p b 0.0005 for self-grooming time; t(18) = 3.040, p=
0.011 for the NOR discrimination index; t(18) = 0.059, p = 0.953 for the time in the center, t(18) = −2.090, p = 0.051 for the latency to enter the center and t(18) = −7.099, p b
0.0005 for the distance travelled in the OF test; t(17) = 2.947, p= 0.009 for open arm entries in the EPM test; t(18) = 2.785, p= 0.012 for the immobility time in the FST test; t(18) =
3.229, p= 0.005 for the adrenal glands weight; t(17) =−5.480, p b 0.0005 for the Gr and t(17) =−1.845, p= 0.094 for theMr. gene expression, unpaired t-test. U(18) = 83.000, p=
0.011 for # of buried marbles; U(18) = 99.000, p b 0.0005, U(18) = 98.000, p b 0.0005 and U(18) = 83.000, p= 0.001 for # of fecal pellets in the OF, NOR and EPM tests, respectively,
Mann-Whitney test. Plasma Corticosterone: F(5;80) = 209.091, p b 0.0005 for the effect of Time, F(1;16) = 8.193, p= 0.011 for the effect of Genotype, F(5;80) = 1.534, p= 0.221 for the
Time × Genotype interaction. Datasets were analyzed with mixed-design ANOVA with Genotype as an independent factor and Time as a repeated measure. Mean values in each time
point were further compared between groups with unpaired t-test.
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positively correlated with the social behavior scores and negatively cor-
related with the repetitive behaviors and anxiety phenotype. For the
S24–7 family, Bilophila and Bacteroides species (all increased in abun-
dance in BTBR mice), a negative association with sociability levels and
a positive association with compulsive and anxiety-like behaviors was
observed (Fig. 7). Given the tight interactions between the gut microbi-
ota and GI functions (Table S3), it is perhaps not surprising that behav-
ioral scores were also associated with changes in the intestinal
serotonin levels and other GI parameters assessed (Fig. S4).
4. Discussion
The BTBR mouse strain is a very popular and useful animal model of
ASD, with a robust autistic-like behavioral phenotype (Meyza et al.,
2013). Herewe show that social behavior deﬁcits in BTBRmice are asso-
ciated with marked GI distress, evidenced by changes in intestinal per-
meability, transit and the ENS morphology, as well as with altered
microbiota composition. BTBR mice displayed profound changes in the
cecal microbiota, with 18 out of 44 identiﬁed bacterial genera being dif-
ferentially altered (Table S2). These included bacterial taxa that have
previously been shown to be important for host health, and some of
them associated with ASD: Akkermansia, Biﬁdobacterium, Blautia,
Desulfovibrio, Biloﬁla, etc. (Kang et al., 2017; Vuong and Hsiao, 2017).
A signiﬁcant reduction in the relative abundance of Blautia and
Biﬁdobacterium genera is of particular interest with respect to GI physi-
ology in BTBR mice. Indeed, Blautia bacteria belong to the Clostridiales
order, representatives ofwhich have been shown tomodulate 5-HTme-
tabolism in the host by increasing the expression of Tph1 in the gut, ac-
tivating 5-HT synthesis and accelerating GI motility (Yano et al., 2015).
Furthermore, Blautia and Biﬁdobacterium species are involved in the
transformation of host bile. Biﬁdobacterium, along with Lactobacillus
and a few other taxa, express bile salt hydrolase enzymes, which carry
out de-conjugation of BAs from taurine or glycine (Begley et al.,
2006); this is the ﬁrst step in bacterial conversion of bile (Joyce and
Gahan, 2016). Of note, lactobacilli also tended to be decreased in the
BTBR gut (Table S2). Unconjugated primary BAs are further transformed
into secondary BAs as a result of 7α-dehydroxylation activity, which is
present in some members of Clostridium cluster XIVa including Blautia
species (Ridlon et al., 2013). Therefore, a substantial loss in Blautia and
Biﬁdobacterium species in the BTBR microbiota strongly suggests that
the efﬁcacy of bacteria-mediated bile transformation, as well as the ef-
fect of bacteria on 5-HT production are impaired in the BTBR intestine.
The follow-up analysis of bile moieties and tryptophan metabolites
in the BTBR gut conﬁrmed the sequencing-based functional predictions.
First, we observed a dramatic increase in all conjugated BAs, as well as a
reduction in secondary BA pool in BTBR fecal matter (Fig. 5d and Fig.
S3). These data indicate that both bile salt hydrolase and 7α-dehydrox-
ylation activities are compromised in the BTBRmicrobiota. Secondly, we
found a marked reduction in 5-HT bioavailability in BTBR small and
large intestine due to a decrease in 5-HT synthesis and an increase in
5-HT breakdown (Fig. 2e–f). Strikingly, intestinal 5-HT levels and Tph1
gene expression were strongly and positively correlated with the rela-
tive abundance of Blautia genus (Fig. 2g, Table S3). Hence, the observed
reduction in the abundance of Blautia species could underlie the deﬁcit
in 5-HT production in the BTBR gut.
Changes in either tryptophan metabolism or the microbial conver-
sion of bile can have a tremendous impact on GI physiology. Secondary
BAs, produced by gut bacteria, have a unique signaling proﬁle in the GI
tract as compared with primary bile moieties. For example, secondary
BAs were shown to activate colonic motility by stimulating the release
Fig. 7. A strong association between behavioral scores and gut microbiota composition A correlation matrix showing positive (red) and negative (blue) associations between behavioral
scores and the relative abundance of bacterial genera in BTBR and C57BL/6 mice. Signiﬁcant correlations are markedwith asterisks. *p b 0.05, **p b 0.01 and ***p b 0.001, Spearman's rank
correlation analysis, Benjamini-Hochberg adjusted p values with a FDR of 0.05.
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of intestinal 5-HT and CGRP (Alemi et al., 2013). Therefore, a reduction
in secondary BA levels could contribute to the delayed colonic transit in
BTBR mice (Fig. 2b–d). Further, tauro-conjugated β-MCA has recently
been shown to be a potent natural antagonist of Fxr receptor in mice
and to inhibit its downstream signaling (Sayin et al., 2013). Hence, an
increase in Tβ-MCA intestinal levels can explain the observed down-
regulation of Fgf15 gene expression in the BTBR ileum (Fig. 5b and d).
In addition to the deﬁcits in bacteria-mediated bile conversion, BTBR
mice displayed a reduction in plasma BA levels, most likely due to a de-
crease in BA synthesis along the classical Cyp7a1-mediated pathway
(Fig. 5a and c). This can have deleterious consequences for the intestine
aswell. BAs are toxic formanybacterial species; they also induce the ex-
pression of anti-microbial defense genes in the host (including iNOS,
RegIIIγ) (Inagaki et al., 2006; Joyce et al., 2014). In fact, a reduction in
the luminal BA levels has been associated with small intestine bacterial
overgrowth, activation of inﬂammation, and subsequent damage to the
epithelium (Inagaki et al., 2006; Lorenzo-Zúñiga et al., 2003). A down-
regulation of iNos (Nos2) gene expression in the ileum of BTBR mice
(Fig. 5b) suggests that anti-microbial defense can be compromised in
the BTBR intestine, which in turn could contribute to the impairment
of small intestine barrier function (Fig. 4a).
Similar to bile moieties, tryptophan metabolites are involved in the
regulation of essential GI functions. 5-HT activates intestinal peristalsis
and electrolyte secretion, supports the development of the ENS and
ampliﬁes inﬂammatory responses in the gut (Ghia et al., 2009;
Heredia et al., 2013; Liu et al., 2009; Mawe and Hoffman, 2013).
Hence, a decrease in 5-HT bioavailability can explain delayed intestinal
transit and reduced activity of electrolyte transport seen in BTBR mice
(Figs. 2a–d, 4f). Interestingly, metabolism of tryptophan along the
kynurenine route also seems to be affected in BTBR mice. The expres-
sion levels of Ido1 and Tdo2 genes, which encode alternative rate-limit-
ing enzymes in this pathway, were markedly altered in the BTBR
intestine (Fig. 2e–f). Tdo2 gene expression is responsive to stress and
is under a tight control of glucocorticoids (Green and Curzon, 1975).
Strikingly, we found an increased expression of Cyp11a1 gene in the
BTBR ileum(Fig. S2b), which could have resulted in elevated production
of corticosterone and an up-regulation of Tdo2 locally in the BTBR ileum
(Fig. 2f). The observed changes in intestinal Ido1 and Tdo2 gene expres-
sion are very unlikely to have a direct effect on the brain in BTBR mice.
Indeed, N90% of tryptophan is catabolized down to kynurenine in the
liver, with liver Tdo2 activity determining the systemic levels of
kynurenine, and the availability of tryptophan for the brain (Kennedy
et al., 2017). To this end, neither the expression of liver Tdo2 nor the
plasma levels of tryptophan was altered in BTBR mice (Fig. S5a–b).
However, this will certainly affect the intestinal levels of kynurenine
and its metabolites (kynurenic and quinolinic acids), and local effects
on the BTBR gut physiology are thus very plausible. For instance,
kynurenic acid is known to slow the intestinal transit by inhibiting the
Fig. 8. Putative mechanisms linking changes in the gut microbiota with GI malfunction in the BTBR mouse model of human ASD. In BTBR mice, autistic-like behavioral phenotype is
associated with altered microbiota and marked GI distress: increased epithelial permeability (1) and delayed intestinal motility (2). (1) Reduced abundance of bile-metabolizing
Biﬁdobacterium species increases the fraction of tauro-conjugated BAs (e.g. tauromuricholic acid (TβMCA)) in the GI tract. TβMCA inhibits Fxr signaling and thus supresses anti-
microbial defense of the host (iNOS, RegIIIγ). We hypothesise that loss of Fxr signaling in BTBR mice causes small intestinal bacterial overgrowth and, as a result, an increase in
epithelial permeability. This effect is further exaggerated by deﬁcient synthesis of BAs, which normally prevent bacterial overgrowth. (2) Healthy intestinal transit relies on many
factors, including the ENS, secondary BAs and 5-HT (all deﬁcient in BTBR mice). Secondary BA levels are reduced; 5-HT bioavailability is decreased due to a lower production (down-
regulation of Tph1) and a higher breakdown (up-regulation of Sert) rates. Lower abundance of clostridia bacteria, including Blautia species, potentially contributes to these changes.
Further, the BTBR myeneric plexus shows reduced numbers of excitatory and inhibitory neurons. All this can cause delayed intestinal motility in BTBR mice.
176 A.V. Golubeva et al. / EBioMedicine 24 (2017) 166–178
enteric NMDA receptors, as well as to dampen the inﬂammatory re-
sponse in the gut (Érces et al., 2012; Kaszaki et al., 2008; Keszthelyi et
al., 2009). Moreover, both 5-HT and kynurenine metabolites can alter
the activity of intestinal vagal afferents, and hence, might directly affect
vagal signaling to the brain (Slattery et al., 2006). Of note, recent evi-
dence suggests altered 5-HT and kynurenine metabolism in ASD
(Boccuto et al., 2013; Lim et al., 2015; Muller et al., 2016).
Altered tryptophanmetabolismand inadequate bacterial conversion
of bile are thus very likely to contribute to both intestinal dysmotility
and impaired gut barrier function in BTBRmice. Maintenance of epithe-
lial integrity is critically important not only for gut health, but also for
brain health. The phenomenon of “leaky” gut has recently been extend-
ed beyondGI disorders, such as irritable bowel syndrome, to psychiatric
diseases, such as depression (Kelly et al., 2015). Dysfunctional intestinal
barrier in BTBR mice can permit themicrobiota to induce low-grade in-
ﬂammation in the gut. This shift towards a pro-inﬂammatory state, par-
ticularly in combination with an anxious phenotype (Fig. 6h–l), can in
turn trigger the activation of neuroinﬂammatory responses in the
brain (Rea et al., 2016; Wohleb et al., 2015) and exaggerate autistic-
like behavioral deﬁcits in BTBR mice. Indeed, the BTBR mouse has
been shown to display a pro-inﬂammatory phenotype that is thought
to contribute to the development of ASD-like behavior (Careaga et al.,
2015; Heo et al., 2011; Onore et al., 2013). Interestingly, we found that
deﬁcits in social behavior in BTBRmicewere accompanied by a decrease
in plasma oxytocin levels (Fig. 6d). Oxytocin is one of the key hormones
involved in supporting the salience of social interactions, and is known
to bemodulated by intestinalmicrobiota (Bufﬁngton et al., 2016; Varian
et al., 2017).
In summary, here we show that the BTBR mouse displays marked
GI dysfunction (Fig. 8). Similar to human ASD, BTBR mice have
“leaky” intestinal epithelium and delayed intestinal transit. We fur-
ther identify deﬁcient bacterial transformation of bile moieties and
impaired tryptophan metabolism in the BTBR intestine as potential
mechanisms underlying GI symptoms in these animals. Taking ad-
vantage of microbiota sequencing and physiological data, we associ-
ate these functional changes with a reduction in the relative
abundance of Biﬁdobacterium and Blautia bacteria in the BTBRmicro-
biota. These data offer speciﬁc targets in the gut microbiota for im-
proving gastrointestinal and, perhaps, behavioral symptomatology
in the BTBR mouse model of autism, and support the concept of mi-
crobiota-based interventions in ASD.
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